In previous studies of the response of normal volunteers to inoculation with respiratory viruses, the inoculum was administered by instillation of liquid into the nose and by a hand nebulizer that delivered a coarse spray to the nasopharynx (1). Observation indicated that much of the virus given by these methods deposited in the nasopharynx, but portions were swallowed, or discharged by coughing, sneezing, or expectoration. Although these studies often resulted in viral infection and illness, it was not possible to assess accurately dose-effect relationships. Furthermore, it was apparent that a full investigation of human response to respiratory viruses should include observations on the effect of inoculation of portions of the respiratory tract other than the nasopharynx.
In previous studies of the response of normal volunteers to inoculation with respiratory viruses, the inoculum was administered by instillation of liquid into the nose and by a hand nebulizer that delivered a coarse spray to the nasopharynx (1) . Observation indicated that much of the virus given by these methods deposited in the nasopharynx, but portions were swallowed, or discharged by coughing, sneezing, or expectoration. Although these studies often resulted in viral infection and illness, it was not possible to assess accurately dose-effect relationships. Furthermore, it was apparent that a full investigation of human response to respiratory viruses should include observations on the effect of inoculation of portions of the respiratory tract other than the nasopharynx.
Inoculation with aerosol offered the possibility of attaining the above objectives. The site of deposition of particles within the respiratory tract and the number of particles deposited is a function of the particle size (2, 3) . It is thus possible to estimate with some accuracy both the site of viral deposition and the amount of virus deposited when aerosols of known particle size containing known amounts of virus are inhaled. Therefore, when preliminary studies demonstrated the feasibility of the use in human volunteers of a small-particle aerosol containing Coxsackie A21 virus (4) , and the properties of the aeorsol had been determined (5) , observations were made on the response of volunteers to graduated doses of the aerosol utilizing three different inocula of Coxsackie A21.
Methods
Volunteers. Volunteers were healthy adult males from several Federal correctional institutions, and the arrangements by which they participated have been described in detail elsewhere (6) . They were housed three to a room and placed in isolation for 2 to 4 days before and 10 to 14 days after inoculation. Examinations were performed daily by physicians having no knowledge of which of several respiratory agents was administered to a particular volunteer.
Virus. The strains of Coxsackie An1 used in these studies were recovered from Marines at Camp Lejeune, N. C., who were infected during the 1959 outbreak (7, 8) . Strain 49882 was passaged once in human embryonic kidney tissue culture (HEK) and had a concentration of 10-TCID50 per ml. The details of preparation, identification, and safety testing of this inoculum have been previously reported (1) . A second pool prepared from strain 48654 was passaged twice in Wistar-26 human embryonic lung fibroblast tissue cultures (HEF) (9) and concentrated 100-fold in the following manner: after one freeze-thaw cycle, the harvest of passage 2 was centrifuged at 2,000 rpm for 20 minutes and the supernate passed through an 800-mA Millipore filter. The filtrate was concentrated 10-fold by vacuum dialysis,' and the concentrate was then homogenized with equal volumes of Genetron in a Virtis "45" homogenizer for 6 separate 1-minute intervals. The aqueous and organic layers were separated by centrifugation at 2,000 rpm for 2 minutes, and the aqueous layer received an additional 10-fold concentration by addition of 0.5% gelatin and centrifugation at 105,000 g for 3 hours in a Spinco model L preparative centrifuge. The resuspended pellets were pooled and distributed in glass ampules, which were sealed and stored at -700 C. This inoculum had a viral concentration of 109' TCID50 per ml and was safety tested in a previously described manner (10) . A third inoculum pool was prepared from three throat swab specimens that were also obtained from Marine Corps recruits at Camp Lejeune, N. C. These specimens were pooled without tissue culture passage, diluted, safety-tested, and stored at -70°C until used.
Inoculation Viral isolation and identification procedures. Nose and throat swabs were obtained from each volunteer before inoculation, daily for 7 days after inoculation, and 3 times weekly for an additional 14 to 18 days. Each swab was agitated in 2 ml of veal infusion broth containing 0.5% bovine albumin and antibiotics, and the specimen fluid was stored at -200 C. Specimens were tested for the presence of virus by inoculating 0.4 ml of specimen fluid into one HEK or HEF tissue culture tube that contained 1.5 ml of equal parts medium 199 and Eagle's MEM, 2% inactivated calf serum, and antibiotics. The cultures were incubated in a roller drum turning at 12 rph at 33 to 340 C, and observed for cytopathic effect for 14 days. Tissue culture fluid and cells were harvested when enterovirus cytopathic effect involved 75 to 100% of the cell sheet. The first and last isolates from nasal and throat swab specimens were identified by hemagglutination-inhibition (HI) with 20 antibody units of specific hyperimmune guinea pig serum (7, 12 and usually persisted for less than 1 day. As shown in Table I , 12 of the 18 infected volunteers who received strain 49882 HEK1 (including the 2 cases later shown to have pneumonia) were clinically diagnosed as febrile acute tracheobronchitis. Characteristic of this syndrome was the occurrence of tracheal and chest pain, the latter usually substernal, and deep cough occurring in paroxysms and associated with chest discomfort.
Cough was usually nonproductive although auscultation of the chest occasionally revealed scattered rhonchi. The lower respiratory tract symptoms were accompanied by symptoms of systemic illness including malaise, myalgias, chilly sensations, sweats, headache, and anorexia. Illness was not limited to the lower respiratory tract, however, since 9 of these 12 volunteers with tracheobronchitis illness also had evidence of upper respiratory tract illness that was characterized by rhinorrhea and nasal obstruction. In addition, 2 of the 12 volunteers had roentgenographic evidence of bronchopneumonia. The details of the course of one of the volunteers who developed bronchopneumonia are shown in Figure 1 . The predominant illness in 4 of the 18 volunteers infected with strain 49882 was upper respiratory although one of these also had cough. The remaining 2 volunteers infected with this strain had evidence of infection without any appaient illness.
In contrast to the predominant lower respiratory tract illness seen with strain 49882 HEK1, the predominant response was upper respiratory illness with strain 48654 HEF2. As shown in Table II strain 48654 HEF2 developed a predominant picture of tracheobronchitis. However, in all other aspects, height and duration of fever, incubation period, and systemic symptoms, the illness responses to both strains were similar.
The incubation period, severity of illness, and anatomical site of involvement for all reported illnesses did not exhibit any definite relationship to inoculating dose. Illness was brief in volunteers receiving both inocula. In 21 of the 22 febrile volunteers, fever was of less than 24 hours duration. Although the total duration of clinically detectable illness varied between 2 to 13 days, most cases were ill for only 2 to 3 days. Often a volunteer would be well one morning, have fever, systemic symptoms, and tracheobronchitis that evening, and exhibit only mild afebrile upper respiratory illness (URI) during the remaining days of illness.
A mild rhinitis not associated with viral infection was seen in five volunteers who received low doses of virus (Tables I and II strain 49882 HEK1 by aerosol (Table III) . Three were infected as determined by viral isolation and antibody rise. The illness seen in these individuals was milder and the period of viral shedding was shorter (mean 5 days) than that seen in infected antibody-free volunteers. The three men with the highest titers (> 256) had acquired this antibody after nasopharyngeal inoculation with Coxsackie A21 about 4 months earlier. All three of these individuals developed an afebrile nasal illness with no detectable infection. No consistent pattern of leukocyte changes or-nasal secretion results occurred in these eight volunteers.
Inoculation with natural virus. In order to evaluate the effect of tissue culture passage on infectivity and virulence, an inoculum containing Discussion In these studies estimates have been made of the HID50 of 2 strains of Coxsackie A21 that had been passaged in tissue cultures of human origin and administered in a small-particle aerosol. Each strain had an HID50 of approximately 30 TCID50 of virus; however, since these estimates were based on inhaled doses, of which only 50 to 75% was retained (2, 3), the actual HID50 were considerably less than 30 TCID50. Virus obtained from naturally occurring cases of illness but not passaged in tissue culture was also given, and the results suggest that this inoculum had about the same degree of infectivity.
Despite the nearly identical HID50 and the other similarities, the anatomic distribution of the illness responses was quite different. Strain 49882 frequently caused tracheobronchitis, which in two cases was accompanied by roentgenographic evidence of pneumonia, whereas no lower respiratory tract illness occurred in those volunteers inoculated with strain 48654. Both strains caused about the same degree of upper respiratory tract involvement.
In a previous study antibody-free volunteers were inoculated in the nasopharynx by coarse spray and drops with 3,000 TCID50 of strain 49882 HEK1 (1). These men developed upper respiratory illness only, which is in contrast to the finding that this same inoculum given by smallparticle aerosol produced both upper and lower respiratory illness. Thus the disparity in distribution of illness resulting when two different strains (49882 HEK1 and 48654 HEF2) were separately administered by the same method was also seen when two different methods were used to administer strain 49882 HEK1. The question arises as to the possible causes for these findings.
The following evidence indicates that there is a marked difference in sites of deposition of virus administered by coarse spray and drops and by small-particle aerosol. In the former method, virus was administered by instillation with a pipette and with a no. 127 DeVilbiss hand atomizer. Excess material given by pipette was swallowed or expectorated. The type of atomizer used has been shown to produce a coarse spray (15) , which by calculation can be shown to be trapped almost exclusively in the nasopharynx (2, 3) . Hence, inoculation of volunteers by this procedure results almost entirely in deposition of virus in the nasal passages and posterior pharynx.
In contrast to this deposition pattern, 80 to 90%o of particles in the size range (0.2 to 3.0-Au diameter) present in the small-particle aerosol will bypass the nasopharynx and be carried to peripheral areas of the lung. The remaining 10 to 20%o will be trapped in the nasopharynx (2, 3) . Since the volunteers inhaled a 10-L dose of aerosol in approximately 10 breaths, a volume larger than the usual tidal volume, it seems likely that complete exchange of alveolar air occurred. Such a result would provide opportunity for virus in the 80 to 90%o of particles that bypassed the nasopharynx to deposit in the alveoli. About one-half of particles reaching the alveoli and adjacent areas will deposit, primarily due to gravity settling. Thus, virus contained in this small-particle aerosol will be deposited throughout the respiratory tract from the nose to the alveoli, but with the greatest concentration in the peripheral areas of the lungs.
These statements are based on the assumption that the particles in the aerosol, which is prepared at 50 to 60%o humidity, did not increase greatly in size as a result of absorption of water in the moisture-saturated air of the respiratory passages. Studies in chambers with controlled humidity indicate that similar aerosol particles increase in size by as much as 2.0 to 2.5 times when exposed to 90%o relative humidity (5) . If the virus were contained in particles 3 u in diameter, about 40% would be removed in the nasal passages and tracheobronchial tree, and deposition in the pulmonary lobules would fall appreciably (2, 3) . However, regardless of any change in size that may occur, substantial deposition in lower respiratory sites is assured.
It is thus apparent that if viral infection were established at the sites of deposition, this would account for the development of upper respiratory illness in those volunteers inoculated by coarse spray and drops (49882 HEK1) and lower respiratory tract illness in those volunteers inoculated with the same strain by means of smallparticle aerosol. The deposition of aerosol inoculum in the nasopharynx would account for the upper respiratory illness as well as the recovery of virus from the nasopharynx before and simultaneously with the onset of illness in all groups. (19) .
The contrasting responses to these two Coxsackie A21 inocula may involve mechanisms more complex than those that have been discussed. Despite similarities in methods of inoculation and in strains of virus that might lead one to expect similar illness responses, significant differences in patterns of disease occurred, which indicates the need for further study of this problem.
The relevance of the present studies to those responses that occur during naturally occurring infection cannot be precisely assessed at the present time. However, sneezing and coughing produce significant numbers of particles of a size that remain airborne for long periods of time (20) . Since throat and nose secretions from persons with naturally and experimentally induced infections with Coxsackie A21 contain 1046 TCID50 per ml, it is reasonable to suppose that the smallparticle aerosol produced by sneezing or coughing may contain the small quantity of virus required to infect man (21, 22) . Thus the method of smallparticle aerosol inoculation used in this study may closely resemble the mechanism of initiation of naturally occurring infection. 
